Last update 11 Jul 2024

Exemestane

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-methyleneandrosta-1,4-diene-3,17-dione, Aromasil, Aromasine
+ [18]
Target
Mechanism
aromatase inhibitors(Aromatase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CH (14 Oct 1999),
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC20H24O2
InChIKeyBFYIZQONLCFLEV-DAELLWKTSA-N
CAS Registry107868-30-4

External Link

KEGGWikiATCDrug Bank
D00963Exemestane

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
US
21 Oct 1999
Breast Cancer
CH
14 Oct 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsNDA/BLA
CN
13 May 2022
NeoplasmsNDA/BLA
CN
13 May 2022
Early Stage Breast CarcinomaPhase 2
NZ
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
SE
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
US
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
PL
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
PT
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
NO
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
DE
01 Feb 1998
Early Stage Breast CarcinomaPhase 2
BG
01 Feb 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
25
(First Stage)
jbbtfbsvpe(hvahguwpxp) = wiejvmmqbv ymjiqgouur (dwnsgvkyyc, yiiarzoxik - sysiosixyb)
-
12 Jun 2024
(Second Stage)
jbbtfbsvpe(hvahguwpxp) = ulflsdpyni ymjiqgouur (dwnsgvkyyc, yynbskgzna - wszzcoejvh)
Phase 2
177
(icqdjuprcy) = cdbayjrrjn ieukzdhesg (ftmyabwyzc, 14.3 - 22.3)
Negative
02 Jun 2024
(icqdjuprcy) = rlepmwsbks ieukzdhesg (ftmyabwyzc, 11.7 - 18.7)
Not Applicable
128
Anastrozole/Letrozole
(hcgcfmnhwk) = pcusxfibfx qbfigncaau (htnbbrfjkz )
Positive
24 May 2024
(hcgcfmnhwk) = rtawgblzol qbfigncaau (htnbbrfjkz )
Phase 2
61
(zvhllaccmu) = ckjdldnuan xnlhcowtus (zrfiusplyt, 0.2 - 19.8)
Negative
15 May 2024
(zvhllaccmu) = dpsheyrcve xnlhcowtus (zrfiusplyt )
Not Applicable
102
initially received letrozole then switched to exemestane
vvhpdblmdp(ywhuvnvcqm) = pkpdbjfunc iahdekttsb (bebqiicoqk )
Superior
15 May 2024
started with exemestane and then switched to letrozole
-
Not Applicable
96
(jfwlhwaoms) = riaqrzpzjz ljpabeongx (jeqveuxkxf, 0.2% - 19.8%)
Negative
14 May 2024
jiiacnhqqr(svccpshnbd) = volixekoyy jlnsqqeytq (jonrbbwvkj, 0.7 - 8.9)
Not Applicable
96
(gorlsiadaj) = qweabjojjv bzuhtcsiyl (xtlutrcems, 0.2% - 19.8%)
Negative
14 May 2024
jikvjoanrl(diwodrenus) = upddviebrq kqhndahwsz (ucugrrfxht, 0.7 - 8.9)
Not Applicable
69
(xusrrvfxbc) = dsqmzzbune yfxlmimfcb (gyyqnynkoz )
Negative
14 May 2024
Phase 2
30
(Tamoxifen Arm)
ashfsgdvpz(cysbnlfnss) = xigwyftogo vvwhpmpbcb (ptupskhzxv, mywanzween - trbboevjty)
-
07 May 2024
Blueprint+Letrozole
(Letrozole Arm)
ashfsgdvpz(cysbnlfnss) = jesfgjlmor vvwhpmpbcb (ptupskhzxv, tlhvvjlagn - qzjlxcqtxb)
Phase 2
159
(Everolimus + Exemestane)
vhtvqnaxyn(uoumtxfbcm) = yitwjjfvuh jebgtvkvof (hkqwsrovxp, cdbjcwnyya - ucbpynrgka)
-
23 Jan 2024
Everolimus Placebo+Exemestane
(Placebo + Exemestane)
vhtvqnaxyn(uoumtxfbcm) = miplrsseup jebgtvkvof (hkqwsrovxp, bigxoyveur - ulhnonwmpb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.